NeurologyOnline.net

Neurology Xagena

Phase IIa clinical trial data on ATL1102 were published in the medical journal Neurology. The article highlights the successful outcomes of the randomised, double-blind, placebo-controlled study in 77 ...


The evaluation of therapeutic choices is needed after 24 doses of Natalizumab ( Tysabri ) in patients with multiple sclerosis ( MS ). A study has evaluated the effect of therapeutic choices on the me ...


No reliable treatment options are known for progressive multifocal leukoencephalopathy with underlying immunodeficiency. Researchers have described successful compassionate use of in a patient with ...


Five-year results from the ENDORSE phase 3 extension study have shown Dimethyl fumarate ( Tecfidera ) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting ...


Many of those who are genetically predisposed to develop atrial fibrillation, which dramatically raises the risk of stroke, can be identified with a blood test. This is shown by new research from Lund ...


Interim results from the second year of the extension study of Alemtuzumab ( Lemtrada ) for multiple sclerosis were presented at the European Committee for Research and Treatment in Multiple Sclerosis ...


The full results from the phase 3 DECIDE clinical trial have shown a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis ( RRMS ) w ...


The phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis ( RMS ) met the primary endpoint, reduction in MRI brain lesion activity. ...


The prognostic significance of age and continuous positive airway pressure ( CPAP ) therapy on cardiovascular disease in patients with sleep apnoea has not been assessed previously. Using nationwid ...


It is studied the applicability of the Acute Physiology and Chronic Health Evaluation II ( APACHE II ) and Simplified Acute Physiology Score II ( SAPS II ) in patients admitted to the intensive care u ...


The FDA-approved trial, A Phase 1, Open-Label, First-in-Human, Feasibility and Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Scler ...


A study has evaluated the ability of Lithium carbonate and Valproate cotreatment to modify the survival rate and functional score of patients with definite sporadic amyotrophic lateral sclerosis ( ALS ...


In the SELECT trial, disease activity was reduced in patients with multiple sclerosis who received Daclizumab high-yield process ( HYP ) for 52 weeks. The primary aim of the SELECTION extension st ...


Uric acid is an antioxidant with neuroprotective effects in experimental models of stroke. Researchers have assessed whether uric acid therapy would improve functional outcomes at 90 days in patients ...


Parkinson's disease psychosis, which includes hallucinations and delusions, is frequent and debilitating in people with Parkinson's disease. Researchers have assessed safety and efficacy of Pimavans ...


A retrospective cohort study using data from a large scale, comprehensive population based state-wide stroke registry in Germany, has assessed the time dependent effectiveness of thrombolytic therapy ...


Although the benefit of reducing blood pressure for primary and secondary prevention of stroke has been established, the effect of antihypertensive treatment in patients with acute ischemic stroke is ...


Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. The ...


There is insufficient evidence to support use of occupational therapy interventions for patients with Parkinson's disease. A study has assessed the efficacy of occupational therapy in improving daily ...


Autoimmunity might be associated with or implicated in sleep and neurodegenerative disorders. Researchers have described the features of a novel neurological syndrome associated with prominent sleep d ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati